Wilex plans rights offering

Monday 6 August 2012

Wilex AG has announced plans to raise approximately €17.3 million in cash, and to convert an existing loan into equity, ahead of a meeting with the FDA to discuss a further development strategy for its cancer diagnostic Redectane.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Germany